Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METAL2: Strategies for Asymptomatic Brain Metastases in NSCLC
NCT02162537Phase 3Terminated
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Dec 2013
- Primary completion
- Mar 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Centre Hospitalier Intercommunal de Créteil. Primary endpoint: Progression-Free Survival up to 90 months. Started Dec 2013; status: terminated.
Beyond the preview
Go deeper on NCT02162537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162537.